Skip to main content
Erschienen in: Obesity Surgery 9/2020

18.04.2020 | Original Contributions

The Positive Effects of a Calorie-Restricting High-Protein Diet Combined with Intragastric Botulinum Toxin Type A Application Among Morbidly Obese Patients: A Prospective, Observational Analysis of Eighty-Seven Grade 2 Obese Patients

verfasst von: Murat Ferhat Ferhatoglu, Abdulcabbar Kartal, Ali Ilker Filiz, Abut Kebudi

Erschienen in: Obesity Surgery | Ausgabe 9/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Many studies evaluating the effect of intragastric botulinum toxin type A injection (IG-BTxA) for the treatment of obesity have been published. However, none of these studies combined this procedure with a calorie-restricting high-protein diet. Herein, we aimed to evaluate the effects of IG-BTxA application combined with a calorie-restricting high-protein diet.

Materials and Methods

This prospective cohort study is conducted with eighty-seven grade 2 obese patients treated between January 2019 and August 2019. Group 1: IG-BTxA + refused to consult the dietitian; group 2: IG-BTxA + get calorie-restricting high-protein diet; group 3: only get a calorie-restricting high-protein diet. Loss of weight, treatment adaptation (visual analog scale score), the status and changes of comorbid conditions, and changes in eating behaviors (Self-Regulation of Eating Behaviour Questionnaire score) were assessed.

Results

Loss of weight, treatment adaptation, and positive behavioral change in eating preferences were significantly higher in group 2 (p = 0.01; p = 0.001; p < 0.01, respectively). Additionally, the decrease in medication requirement for diabetes and hypertension was higher in group 2 (p < 0.05).

Conclusion

IG-BTxA application before calorie-restricting high-protein diet facilitates adaptation to the new diet style and helps to lose weight faster in grade 2 obese patients. Also, more positive results were achieved in terms of controlling comorbid diseases.
Literatur
1.
Zurück zum Zitat Bassett MT, Perl S. Obesity: the public health challenge of our time. Am J Public Health. 2004;94:1477.CrossRef Bassett MT, Perl S. Obesity: the public health challenge of our time. Am J Public Health. 2004;94:1477.CrossRef
2.
Zurück zum Zitat Hurt RT, Kulisek C, Buchanan LA, et al. The obesity epidemic: challenges, health initiatives, and implications for gastroenterologists. Gastroenterol Hepatol (N Y). 2010;6:780–92. Hurt RT, Kulisek C, Buchanan LA, et al. The obesity epidemic: challenges, health initiatives, and implications for gastroenterologists. Gastroenterol Hepatol (N Y). 2010;6:780–92.
3.
Zurück zum Zitat Mittermair R, Keller C, Geibel J. Intragastric injection of botulinum toxin A for the treatment of obesity. Obes Surg. 2007;17:732–6.CrossRef Mittermair R, Keller C, Geibel J. Intragastric injection of botulinum toxin A for the treatment of obesity. Obes Surg. 2007;17:732–6.CrossRef
4.
Zurück zum Zitat Allison DB, Fontaine KR, Manson JE, et al. Annual deaths attributable to obesity in the United States. JAMA. 1999;282:1530–8.CrossRef Allison DB, Fontaine KR, Manson JE, et al. Annual deaths attributable to obesity in the United States. JAMA. 1999;282:1530–8.CrossRef
5.
Zurück zum Zitat Coskun H, Duran Y, Dilege E, et al. Effect on gastric emptying and weight reduction of botulinum toxin-A injection into the gastric antral layer: an experimental study in the obese rat model. Obes Surg. 2005;15:1137–43.CrossRef Coskun H, Duran Y, Dilege E, et al. Effect on gastric emptying and weight reduction of botulinum toxin-A injection into the gastric antral layer: an experimental study in the obese rat model. Obes Surg. 2005;15:1137–43.CrossRef
6.
Zurück zum Zitat Picot J, Jones J, Colquitt JL, et al. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess. 2009;13:1–190.CrossRef Picot J, Jones J, Colquitt JL, et al. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess. 2009;13:1–190.CrossRef
7.
Zurück zum Zitat Meunier FA, Schiavo G, Molgó J. Botulinumneurotoxinss: from paralysis to the recovery of functional neuromuscular transmission. J Physiol. 2002;96:105–13. Meunier FA, Schiavo G, Molgó J. Botulinumneurotoxinss: from paralysis to the recovery of functional neuromuscular transmission. J Physiol. 2002;96:105–13.
8.
Zurück zum Zitat Junior AC, Savassi-Rocha PR, Vaz Coelho LG, et al. Botulinum a toxin injected into the gastric wall for the treatment of class III obesity: a pilot study. Obes Surg. 2006;16:335–43.CrossRef Junior AC, Savassi-Rocha PR, Vaz Coelho LG, et al. Botulinum a toxin injected into the gastric wall for the treatment of class III obesity: a pilot study. Obes Surg. 2006;16:335–43.CrossRef
9.
Zurück zum Zitat Osio M, Mailland E, Muscia F, et al. Botulinum neurotoxin-a does not spread to distant muscles after intragastric injection: a double-blind single-fiber electromyography study. Muscle Nerve. 2010;42:165–9.CrossRef Osio M, Mailland E, Muscia F, et al. Botulinum neurotoxin-a does not spread to distant muscles after intragastric injection: a double-blind single-fiber electromyography study. Muscle Nerve. 2010;42:165–9.CrossRef
10.
Zurück zum Zitat Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults--the evidence report. National Institutes of Health. Obes Res. 1998;2:51–209. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults--the evidence report. National Institutes of Health. Obes Res. 1998;2:51–209.
11.
Zurück zum Zitat Aasprang A, Andersen JR, Våge V, et al. Ten-year changes in health-related quality of life after biliopancreatic diversion with duodenal switch. Surg Obes Relat Dis. 2016;12:1594–600.CrossRef Aasprang A, Andersen JR, Våge V, et al. Ten-year changes in health-related quality of life after biliopancreatic diversion with duodenal switch. Surg Obes Relat Dis. 2016;12:1594–600.CrossRef
12.
Zurück zum Zitat Kliemann N, Beeken RJ, Wardle J, et al. Development and validation of the self-regulation of eating behaviour questionnaire for adults. Int J Behav Nutr Phys Act. 2016;13:87.CrossRef Kliemann N, Beeken RJ, Wardle J, et al. Development and validation of the self-regulation of eating behaviour questionnaire for adults. Int J Behav Nutr Phys Act. 2016;13:87.CrossRef
13.
Zurück zum Zitat Liu SY, Wong SK, Lam CC, et al. Long-term results on weight loss and diabetes remission after laparoscopic sleeve gastrectomy for a morbidly obese Chinese population. Obes Surg. 2015;25:1901–8.CrossRef Liu SY, Wong SK, Lam CC, et al. Long-term results on weight loss and diabetes remission after laparoscopic sleeve gastrectomy for a morbidly obese Chinese population. Obes Surg. 2015;25:1901–8.CrossRef
14.
Zurück zum Zitat Flores L, Vidal J, Canivell S, et al. Hypertension remission 1 year after bariatric surgery: predictive factors. Surg Obes Relat Dis. 2014;10:661–5.CrossRef Flores L, Vidal J, Canivell S, et al. Hypertension remission 1 year after bariatric surgery: predictive factors. Surg Obes Relat Dis. 2014;10:661–5.CrossRef
15.
Zurück zum Zitat Sada A, Asaad M, Reidt WS, et al. Are in-person post-operative clinic visits necessary to detect complications among bariatric surgery patients? Obes Surg 2019 [Ahead of print- online print] Sada A, Asaad M, Reidt WS, et al. Are in-person post-operative clinic visits necessary to detect complications among bariatric surgery patients? Obes Surg 2019 [Ahead of print- online print]
16.
Zurück zum Zitat Bigalke H, Habermann E. Blockade by tetanus and botulinum A toxin of postganglionic cholinergic nerve endings in the myenteric plexus. Naunyn Schmiedeberg’s Arch Pharmacol. 1980;312:255–63.CrossRef Bigalke H, Habermann E. Blockade by tetanus and botulinum A toxin of postganglionic cholinergic nerve endings in the myenteric plexus. Naunyn Schmiedeberg’s Arch Pharmacol. 1980;312:255–63.CrossRef
17.
Zurück zum Zitat Jones OM, Brading AF, Mortensen NJ. Mechanism of action of botulinum toxin on the internal anal sphincter. Br J Surg. 2004;9:224–8.CrossRef Jones OM, Brading AF, Mortensen NJ. Mechanism of action of botulinum toxin on the internal anal sphincter. Br J Surg. 2004;9:224–8.CrossRef
18.
Zurück zum Zitat James AN, Ryan JP, Parkman HP. Inhibitory effects of botulinum toxin on pyloric and antral smooth muscle. Am J Physiol Gastrointest Liver Physiol. 2003;285:291–7.CrossRef James AN, Ryan JP, Parkman HP. Inhibitory effects of botulinum toxin on pyloric and antral smooth muscle. Am J Physiol Gastrointest Liver Physiol. 2003;285:291–7.CrossRef
19.
Zurück zum Zitat Topazian M, Camilleri M, De La Mora-Levy J, et al. Endoscopic ultrasound-guided gastric botulinum toxin injections in obese subjects: a pilot study. Obes Surg. 2008;18:401–7.CrossRef Topazian M, Camilleri M, De La Mora-Levy J, et al. Endoscopic ultrasound-guided gastric botulinum toxin injections in obese subjects: a pilot study. Obes Surg. 2008;18:401–7.CrossRef
20.
Zurück zum Zitat Albani G, Petroni M, Mauro A, et al. Safety and efficacy of therapy with botulinum toxin in obesity: a pilot study. J Gastroenterol. 2005;40:833–5.CrossRef Albani G, Petroni M, Mauro A, et al. Safety and efficacy of therapy with botulinum toxin in obesity: a pilot study. J Gastroenterol. 2005;40:833–5.CrossRef
21.
Zurück zum Zitat Gui D, Mingrone G, Valenza V, et al. Effect of botulinum toxin antral injection on gastric emptying and weight reduction in obese patients: a pilot study. Aliment Pharmacol Ther. 2006;23:675–80.CrossRef Gui D, Mingrone G, Valenza V, et al. Effect of botulinum toxin antral injection on gastric emptying and weight reduction in obese patients: a pilot study. Aliment Pharmacol Ther. 2006;23:675–80.CrossRef
22.
Zurück zum Zitat Garcia-Compean D, Mendoza-Fuerte E, Martinez J, et al. Endoscopic injection of botulinum toxin in the gastric antrum for the treatment of obesity. Results of a pilot study. Gastroenterol Clin Biol. 2005;29:789–91.CrossRef Garcia-Compean D, Mendoza-Fuerte E, Martinez J, et al. Endoscopic injection of botulinum toxin in the gastric antrum for the treatment of obesity. Results of a pilot study. Gastroenterol Clin Biol. 2005;29:789–91.CrossRef
23.
Zurück zum Zitat Foschi D, Corsi F, Lazzaroni M, et al. Treatment of morbid obesity by intraparieto gastric administration of botulinum toxin: a randomized, double-blind, controlled study. Int J Obes. 2007;31:707–12.CrossRef Foschi D, Corsi F, Lazzaroni M, et al. Treatment of morbid obesity by intraparieto gastric administration of botulinum toxin: a randomized, double-blind, controlled study. Int J Obes. 2007;31:707–12.CrossRef
24.
Zurück zum Zitat Li L, Liu QS, Liu WH, et al. Treatment of obesity by endoscopic gastric intramural injection of botulinum toxin A: a randomized clinical trial. Hepato-Gastroenterology. 2012;59:2003–7.PubMed Li L, Liu QS, Liu WH, et al. Treatment of obesity by endoscopic gastric intramural injection of botulinum toxin A: a randomized clinical trial. Hepato-Gastroenterology. 2012;59:2003–7.PubMed
25.
Zurück zum Zitat Peeters TL. Potential of ghrelin as a therapeutic approach for gastrointestinal motility disorders. Curr Opin Pharmacol. 2006;6:553–8.CrossRef Peeters TL. Potential of ghrelin as a therapeutic approach for gastrointestinal motility disorders. Curr Opin Pharmacol. 2006;6:553–8.CrossRef
26.
Zurück zum Zitat Rollnik J, Meier P, Manns M, et al. Antral injections of botulinum A toxin for the treatment of obesity. Ann Intern Med. 2003;138:359–60.CrossRef Rollnik J, Meier P, Manns M, et al. Antral injections of botulinum A toxin for the treatment of obesity. Ann Intern Med. 2003;138:359–60.CrossRef
27.
Zurück zum Zitat Helmiö M, Victorzon M, Ovaska J, et al. Comparison of short-term outcome of laparoscopic sleeve gastrectomy and gastric bypass in the treatment of morbid obesity: a prospective randomized controlled multicenter SLEEVEPASS study with 6-month follow-up. Scand J Surg. 2014;103:175–81.CrossRef Helmiö M, Victorzon M, Ovaska J, et al. Comparison of short-term outcome of laparoscopic sleeve gastrectomy and gastric bypass in the treatment of morbid obesity: a prospective randomized controlled multicenter SLEEVEPASS study with 6-month follow-up. Scand J Surg. 2014;103:175–81.CrossRef
28.
Zurück zum Zitat Salminen P, Helmiö M, Ovaska J, et al. Effect of laparoscopic sleeve gastrectomy vs. laparoscopic Roux-en-Y gastric bypass on weight loss at 5 years among patients with morbid obesity: the SLEEVEPASS randomized clinical trial. JAMA. 2018;319:241–54.CrossRef Salminen P, Helmiö M, Ovaska J, et al. Effect of laparoscopic sleeve gastrectomy vs. laparoscopic Roux-en-Y gastric bypass on weight loss at 5 years among patients with morbid obesity: the SLEEVEPASS randomized clinical trial. JAMA. 2018;319:241–54.CrossRef
29.
Zurück zum Zitat Peterli R, Wölnerhanssen BK, Peters T, et al. Effect of laparoscopic sleeve gastrectomy vs. laparoscopic Roux-en-Y gastric bypass on weight loss in patients with morbid obesity: the SM-BOSS randomized clinical trial. JAMA. 2018;319:255–65.CrossRef Peterli R, Wölnerhanssen BK, Peters T, et al. Effect of laparoscopic sleeve gastrectomy vs. laparoscopic Roux-en-Y gastric bypass on weight loss in patients with morbid obesity: the SM-BOSS randomized clinical trial. JAMA. 2018;319:255–65.CrossRef
30.
Zurück zum Zitat Bhandari M, Reddy M, Kosta S, et al. Laparoscopic sleeve gastrectomy versus laparoscopic gastric bypass: a retrospective cohort study. Int J Surg. 2019;67:47–53.CrossRef Bhandari M, Reddy M, Kosta S, et al. Laparoscopic sleeve gastrectomy versus laparoscopic gastric bypass: a retrospective cohort study. Int J Surg. 2019;67:47–53.CrossRef
31.
Zurück zum Zitat Garg H, Priyadarshini P, Aggarwai S, et al. Comparative study of outcomes following laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy in morbidly obese patients: a cas- control study. World J Gastrointest Endosc. 2017;9:162–70.CrossRef Garg H, Priyadarshini P, Aggarwai S, et al. Comparative study of outcomes following laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy in morbidly obese patients: a cas- control study. World J Gastrointest Endosc. 2017;9:162–70.CrossRef
32.
Zurück zum Zitat Graham B, Green A, James M, et al. Measuring patient satisfaction in orthopaedic surgery. JBJS. 2015;97:80–4.CrossRef Graham B, Green A, James M, et al. Measuring patient satisfaction in orthopaedic surgery. JBJS. 2015;97:80–4.CrossRef
33.
Zurück zum Zitat De Vet H, Terwee C, Mokkink L, et al. Development of a measure- ment instrument. Measurement in medicine: a practical guide. Practical guides to biostatistics and epidemiology. Cambridge: Cambridge University Press; 2011. p. 30–64. De Vet H, Terwee C, Mokkink L, et al. Development of a measure- ment instrument. Measurement in medicine: a practical guide. Practical guides to biostatistics and epidemiology. Cambridge: Cambridge University Press; 2011. p. 30–64.
34.
Zurück zum Zitat Rosenzveig A, Kuspinar A, Daskalopoulou SS, et al. Toward patient-centered care: a systematic review of how to ask questions that matter to patients. Medicine. 2014;93:120.CrossRef Rosenzveig A, Kuspinar A, Daskalopoulou SS, et al. Toward patient-centered care: a systematic review of how to ask questions that matter to patients. Medicine. 2014;93:120.CrossRef
35.
Zurück zum Zitat Arman GA, Himpens J, Dhaenens J, et al. Long-term (11+years) outcomes in weight, patient satisfaction, comorbidities, and gastro- esophageal reflux treatment after laparoscopic sleeve gastrectomy. Surg Obes Relat Dis. 2016;12:1778–86.CrossRef Arman GA, Himpens J, Dhaenens J, et al. Long-term (11+years) outcomes in weight, patient satisfaction, comorbidities, and gastro- esophageal reflux treatment after laparoscopic sleeve gastrectomy. Surg Obes Relat Dis. 2016;12:1778–86.CrossRef
Metadaten
Titel
The Positive Effects of a Calorie-Restricting High-Protein Diet Combined with Intragastric Botulinum Toxin Type A Application Among Morbidly Obese Patients: A Prospective, Observational Analysis of Eighty-Seven Grade 2 Obese Patients
verfasst von
Murat Ferhat Ferhatoglu
Abdulcabbar Kartal
Ali Ilker Filiz
Abut Kebudi
Publikationsdatum
18.04.2020
Verlag
Springer US
Erschienen in
Obesity Surgery / Ausgabe 9/2020
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-020-04597-y

Weitere Artikel der Ausgabe 9/2020

Obesity Surgery 9/2020 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.